Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2726-2734

  Saggar, Jasdeep K ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

drug distribution; drug penetration; hypoxia activated pro drug; pharmacodynamic markers; TH 302; tumor microenvironment

Indexed keywords

CASPASE 3; CASPASE 6; DOCETAXEL; DOXORUBICIN; HISTONE GAMMA H2AX; KI 67 ANTIGEN; N,N' BIS(2 BROMOETHYL)PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYL ESTER; NUCLEAR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DAMAGE; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

DRUG DISTRIBUTION; DRUG PENETRATION; HYPOXIA-ACTIVATED PRO-DRUG; PHARMACODYNAMIC MARKERS; TH-302; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL HYPOXIA; DOXORUBICIN; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; PRODRUGS; PROSTATIC NEOPLASMS; TAXOIDS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896341950     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28595     Document Type: Article

References (29)

1. Brown JM, Wilson WR,. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47.
2. Hill RP, Bristow RG,. The basic science of oncology, 5th edn. Unites state of America: McGraw-Hill Companies, 2013. 575.
3. Minchinton AI, Tannock IF,. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
4. Wilson WR, Hay MP,. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
5. Yu B, Yang M, Shi L, et al. Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain. Sci Rep 2012; 2: 436.
6. Peters KB, Brown JM,. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002; 62: 5248-53.
7. Reddy SB, Williamson SK,. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Invest Drugs 2009; 18: 77-87.
8. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28: 2989-95.
9. Williamson SK, Crowley JJ, Lara PN, Jr, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005; 23: 9097-104.
10. Hicks KO, Pruijn FB, Secomb TW, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006; 98: 1118-28.
11. Sun JD, Liu Q, Wang J, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012; 18: 758-70.
12. Liu Q, Sun JD, Wang J, et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012; 69: 1487-98.
13. Borad MJ, Reddy S, Bahary N, et al. Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer. Am Assoc Cancer Res 2012.
14. Tredan O, Garbens AB, Lalani AS, et al. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res 2009; 69: 940-7.
15. Saggar JK, Fung AS, Patel KJ, et al. Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Mol Cancer Ther 2013; 12: 542-52.
16. Fung AS, Wu L, Tannock IF,. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res 2009; 15: 5389-95.
17. Patel KJ, Tannock IF,. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 2009; 9: 356.
18. Primeau AJ, Rendon A, Hedley D, et al. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11: 8782-8.
19. Sun JD, Liu Q, Ahluwalia D, et al. Complementary chemotherapies with TH-302, a novel hypoxia activated prodrug: optimization of dosing regimens and schedules for study in phase 1/2 with docetaxel, gemcitabine, pemetrexed, and doxorubicin. Biosymposia: Hypoxia, Ischemia and Inflammation 2008.
20. Trotter MJ, Chaplin DJ, Olive PL,. Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer 1989; 59: 706-9.
21. Janicke RU, Sprengart ML, Wati MR, et al. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357-60.
22. Inoue S, Browne G, Melino G, et al. Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ 2009; 16: 1053-61.
23. Fung AS, Jonkman J, Tannock IF,. Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. Neoplasia 2012; 14: 324-34.
24. Lankelma J, Dekker H, Luque FR, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999; 5: 1703-7.
25. Hu J, Handisides DR, Van Valckenborgh E, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010; 116: 1524-7.
26. Weiss GJ, Infante JR, Chiorean EG, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17: 2997-3004.
27. Meng F, Evans JW, Bhupathi D, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2012; 11: 740-51.
28. Keyer K, Imlay JA,. Superoxide accelerates DNA damage by elevating free-iron levels. Proc Natl Acad Sci USA 1996; 93: 13635-40.
29. Ganjoo KN, Cranmer LD, Butrynski JE, et al. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 2011; 80: 50-6.